➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Baxter
Boehringer Ingelheim
Johnson and Johnson
McKinsey

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

EVAMIST Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Evamist patents expire, and when can generic versions of Evamist launch?

Evamist is a drug marketed by Perrigo Pharma Intl and is included in one NDA. There is one patent protecting this drug.

This drug has seventeen patent family members in ten countries.

The generic ingredient in EVAMIST is estradiol. There are seventy-five drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the estradiol profile page.

US ANDA Litigation and Generic Entry Outlook for Evamist

A generic version of EVAMIST was approved as estradiol by MAYNE PHARMA on March 14th, 1996.

  Start Trial

Drug patent expirations by year for EVAMIST
Drug Prices for EVAMIST

See drug prices for EVAMIST

Drug Sales Revenue Trends for EVAMIST

See drug sales revenues for EVAMIST

Recent Clinical Trials for EVAMIST

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lumara Health, Inc.Phase 3

See all EVAMIST clinical trials

Pharmacology for EVAMIST
Drug ClassEstrogen
Mechanism of ActionEstrogen Receptor Agonists

US Patents and Regulatory Information for EVAMIST

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo Pharma Intl EVAMIST estradiol SPRAY;TRANSDERMAL 022014-001 Jul 27, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for EVAMIST

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Perrigo Pharma Intl EVAMIST estradiol SPRAY;TRANSDERMAL 022014-001 Jul 27, 2007   Start Trial   Start Trial
Perrigo Pharma Intl EVAMIST estradiol SPRAY;TRANSDERMAL 022014-001 Jul 27, 2007   Start Trial   Start Trial
Perrigo Pharma Intl EVAMIST estradiol SPRAY;TRANSDERMAL 022014-001 Jul 27, 2007   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for EVAMIST

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0901368 91973 Luxembourg   Start Trial 91973, EXPIRES: 20220219
1769785 CA 2012 00011 Denmark   Start Trial
1214076 49/2008 Austria   Start Trial PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
0901368 C300523 Netherlands   Start Trial PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
McKesson
Harvard Business School
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.